Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?

Hepatocellular carcinoma (HCC) is a lethal disease and unfortunately, most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor. For patients with initially unresectable HCC (uHCC), transarterial chemoembolization (TACE) was the mainstream treatment. Lately,...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastrointestinal oncology 2024-12, Vol.16 (12), p.4753-4756
Main Authors: Centrone, Natalia, Serrano Uson Junior, Pedro Luiz
Format: Article
Language:English
Subjects:
Letter to the Editor
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c239t-bea4d8490639372c2ca7b28d52ca8b7a11120ae1c7c6afed68aa53651b9f9c2c3
container_end_page 4756
container_issue 12
container_start_page 4753
container_title World journal of gastrointestinal oncology
container_volume 16
creator Centrone, Natalia
Serrano Uson Junior, Pedro Luiz
description Hepatocellular carcinoma (HCC) is a lethal disease and unfortunately, most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor. For patients with initially unresectable HCC (uHCC), transarterial chemoembolization (TACE) was the mainstream treatment. Lately, the incorporation of immune checkpoint inhibitors and antiangiogenics for the treatment of metastatic disease has paved the way for significant improvements in the treatment of initially uHCC. In this editorial we will discuss an article that evaluated ICI combinations with lenvatinib and TACE for the treatment of uHCC patients, and highlight future advances in the field.
doi_str_mv 10.4251/wjgo.v16.i12.4753
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11577365</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146853965</sourcerecordid><originalsourceid>FETCH-LOGICAL-c239t-bea4d8490639372c2ca7b28d52ca8b7a11120ae1c7c6afed68aa53651b9f9c2c3</originalsourceid><addsrcrecordid>eNpVkd9uFSEQxjdGY5vaB_DGcOmF5wgL7J-rxpxYNWnijV6TgZ3tUllYgT2Nvo1vWtbWpnIBQ_jmmxl-VfWa0b2oJXt_e3Md9kfW7C2r96KV_Fl1ynrR7WRNxfMn8Ul1ntINLUuIljL6sjrhfdN2HZWn1Z9DmLX1kG3wiYSROPTHcvNWE_ADsfO8eiRmQvNjCdZnYv1ktc0hJrK4NZEcwSeIGaMFtwnngLMOzv7-a_qO2ERsJnlCskQ7I8nbNoZIVh8xocmgHZIJF8jBoHOrg0gMRGN9mOHiVfViBJfw_OE8q75ffvx2-Ly7-vrpy-HD1c7UvM87jSCGTvS04T1va1MbaHXdDbIEnW6BMVZTQGZa08CIQ9MBSN5IpvuxL2p-Vl3c-y6rnnEw6MtkTm09Q_ylAlj1_4u3k7oOR8WYbNviVBzePjjE8HPFlNVs0zYReAxrUpyJppPl7zcpu5eaGFKKOD7WYVRteNWGVxW8quBVG96S8-Zpg48Z_2DyO0pEqS4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146853965</pqid></control><display><type>article</type><title>Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?</title><source>Open Access: PubMed Central</source><creator>Centrone, Natalia ; Serrano Uson Junior, Pedro Luiz</creator><creatorcontrib>Centrone, Natalia ; Serrano Uson Junior, Pedro Luiz</creatorcontrib><description>Hepatocellular carcinoma (HCC) is a lethal disease and unfortunately, most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor. For patients with initially unresectable HCC (uHCC), transarterial chemoembolization (TACE) was the mainstream treatment. Lately, the incorporation of immune checkpoint inhibitors and antiangiogenics for the treatment of metastatic disease has paved the way for significant improvements in the treatment of initially uHCC. In this editorial we will discuss an article that evaluated ICI combinations with lenvatinib and TACE for the treatment of uHCC patients, and highlight future advances in the field.</description><identifier>ISSN: 1948-5204</identifier><identifier>EISSN: 1948-5204</identifier><identifier>DOI: 10.4251/wjgo.v16.i12.4753</identifier><identifier>PMID: 39678805</identifier><language>eng</language><publisher>China: Baishideng Publishing Group Inc</publisher><subject>Letter to the Editor</subject><ispartof>World journal of gastrointestinal oncology, 2024-12, Vol.16 (12), p.4753-4756</ispartof><rights>The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.</rights><rights>The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c239t-bea4d8490639372c2ca7b28d52ca8b7a11120ae1c7c6afed68aa53651b9f9c2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577365/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577365/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39678805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Centrone, Natalia</creatorcontrib><creatorcontrib>Serrano Uson Junior, Pedro Luiz</creatorcontrib><title>Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?</title><title>World journal of gastrointestinal oncology</title><addtitle>World J Gastrointest Oncol</addtitle><description>Hepatocellular carcinoma (HCC) is a lethal disease and unfortunately, most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor. For patients with initially unresectable HCC (uHCC), transarterial chemoembolization (TACE) was the mainstream treatment. Lately, the incorporation of immune checkpoint inhibitors and antiangiogenics for the treatment of metastatic disease has paved the way for significant improvements in the treatment of initially uHCC. In this editorial we will discuss an article that evaluated ICI combinations with lenvatinib and TACE for the treatment of uHCC patients, and highlight future advances in the field.</description><subject>Letter to the Editor</subject><issn>1948-5204</issn><issn>1948-5204</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkd9uFSEQxjdGY5vaB_DGcOmF5wgL7J-rxpxYNWnijV6TgZ3tUllYgT2Nvo1vWtbWpnIBQ_jmmxl-VfWa0b2oJXt_e3Md9kfW7C2r96KV_Fl1ynrR7WRNxfMn8Ul1ntINLUuIljL6sjrhfdN2HZWn1Z9DmLX1kG3wiYSROPTHcvNWE_ADsfO8eiRmQvNjCdZnYv1ktc0hJrK4NZEcwSeIGaMFtwnngLMOzv7-a_qO2ERsJnlCskQ7I8nbNoZIVh8xocmgHZIJF8jBoHOrg0gMRGN9mOHiVfViBJfw_OE8q75ffvx2-Ly7-vrpy-HD1c7UvM87jSCGTvS04T1va1MbaHXdDbIEnW6BMVZTQGZa08CIQ9MBSN5IpvuxL2p-Vl3c-y6rnnEw6MtkTm09Q_ylAlj1_4u3k7oOR8WYbNviVBzePjjE8HPFlNVs0zYReAxrUpyJppPl7zcpu5eaGFKKOD7WYVRteNWGVxW8quBVG96S8-Zpg48Z_2DyO0pEqS4</recordid><startdate>20241215</startdate><enddate>20241215</enddate><creator>Centrone, Natalia</creator><creator>Serrano Uson Junior, Pedro Luiz</creator><general>Baishideng Publishing Group Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20241215</creationdate><title>Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?</title><author>Centrone, Natalia ; Serrano Uson Junior, Pedro Luiz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c239t-bea4d8490639372c2ca7b28d52ca8b7a11120ae1c7c6afed68aa53651b9f9c2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Letter to the Editor</topic><toplevel>online_resources</toplevel><creatorcontrib>Centrone, Natalia</creatorcontrib><creatorcontrib>Serrano Uson Junior, Pedro Luiz</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastrointestinal oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Centrone, Natalia</au><au>Serrano Uson Junior, Pedro Luiz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?</atitle><jtitle>World journal of gastrointestinal oncology</jtitle><addtitle>World J Gastrointest Oncol</addtitle><date>2024-12-15</date><risdate>2024</risdate><volume>16</volume><issue>12</issue><spage>4753</spage><epage>4756</epage><pages>4753-4756</pages><issn>1948-5204</issn><eissn>1948-5204</eissn><abstract>Hepatocellular carcinoma (HCC) is a lethal disease and unfortunately, most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor. For patients with initially unresectable HCC (uHCC), transarterial chemoembolization (TACE) was the mainstream treatment. Lately, the incorporation of immune checkpoint inhibitors and antiangiogenics for the treatment of metastatic disease has paved the way for significant improvements in the treatment of initially uHCC. In this editorial we will discuss an article that evaluated ICI combinations with lenvatinib and TACE for the treatment of uHCC patients, and highlight future advances in the field.</abstract><cop>China</cop><pub>Baishideng Publishing Group Inc</pub><pmid>39678805</pmid><doi>10.4251/wjgo.v16.i12.4753</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1948-5204
ispartof World journal of gastrointestinal oncology, 2024-12, Vol.16 (12), p.4753-4756
issn 1948-5204
1948-5204
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11577365
source Open Access: PubMed Central
subjects Letter to the Editor
title Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A14%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combinations%20of%20lenvatinib%20and%20immune%20checkpoint%20inhibitors%20plus%20transarterial%20chemoembolization,%20is%20it%20the%20prime%20time%20for%20unresectable%20hepatocellular%20carcinoma?&rft.jtitle=World%20journal%20of%20gastrointestinal%20oncology&rft.au=Centrone,%20Natalia&rft.date=2024-12-15&rft.volume=16&rft.issue=12&rft.spage=4753&rft.epage=4756&rft.pages=4753-4756&rft.issn=1948-5204&rft.eissn=1948-5204&rft_id=info:doi/10.4251/wjgo.v16.i12.4753&rft_dat=%3Cproquest_pubme%3E3146853965%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c239t-bea4d8490639372c2ca7b28d52ca8b7a11120ae1c7c6afed68aa53651b9f9c2c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3146853965&rft_id=info:pmid/39678805&rfr_iscdi=true